Considerations for clinically-relevant nanomedicine therapies for chronic diseases

about

Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.Quo vadis nanomedicine?Recent advances in "smart" delivery systems for extended drug release in cancer therapy

P2860

Q28821119-636A3044-EC89-4ED4-9DD7-B51E9B17A704 Q47371950-454A5A22-2CCD-459A-BC0D-7A0951ABAACF Q58735813-C1D28913-A368-47C4-BF0B-DF71A909F2C9

P2860

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

Item

http://www.wikidata.org/entity/Q58073496

description

im Oktober 2015 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2015

@uk

name

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

@en

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

@nl

type

Item

label

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

@en

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

@nl

prefLabel

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

@en

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

@nl

P1476

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

@en

P2860

Effectiveness of Long-Acting Reversible Contraception

Nanopharmaceuticals (part 2): products in the pipeline

The big picture on nanomedicine: the state of investigational and approved nanomedicine products

Nanomedicine: techniques, potentials, and ethical implications.

Nanopharmaceuticals (part 1): products on the market.

Patient adherence to treatment: three decades of research. A comprehensive review.

Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.

Advancing the field of drug delivery: taking aim at cancer.

Cancer nanomedicines: so many papers and so few drugs!

Medication compliance and persistence: terminology and definitions.

P304

3103-3107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/NNM.15.135

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Owen

Steven P. Rannard

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26446297

http://www.w3.org/2001/XMLSchema#string

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

about

P2860

P2860

Considerations for clinically-relevant nanomedicine therapies for chronic diseases

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698